Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
DCF Valuation
Base-case fair value
$73.12
Intrinsic $97.49 · 25% MOS
Current price: $43.52
Base-case summary
Our base-case DCF for Novo Nordisk A S (NVO) projects 10 years of free cash flow growth at 2.0% for years 1–5 and 1.0% for years 6–10, anchored to a default 8% growth assumption, then applies a 2.5% perpetual growth rate and a 8.0% discount rate. Starting from $31.0B in trailing free cash flow, this produces an intrinsic value of $97.49 per share. A 25% safety margin gives a fair value of $73.12, suggesting the stock is currently 68% undervalued against the $43.52 market price.
See 3 scenarios side by side
Conservative, Base, and Optimistic fair values, plus the sensitivity matrix and FCF history. Free account.
Model inputs
TTM Free Cash Flow
$31.0B
Cash & equivalents
$27.0B
Total debt
$131.0B
Shares outstanding
4.4B